Tzield: The First FDA-Approved Drug to Delay Type 1 Diabetes in Children

Type 1 diabetes is a chronic autoimmune disease where the body's immune system attacks the insulin-producing beta cells in the pancreas. While it affects people of all ages, it disproportionately impacts children and adolescents, bringing substantial medical and psychosocial burden to families.

A key insight from recent research is that type 1 diabetes develops over time. For years before symptoms appear, the immune system is quietly attacking beta cells—a phase called stage 2. Once blood sugar problems become noticeable, the disease has progressed to stage 3. This progression creates a window of opportunity: treating the disease before stage 3 arrives may slow or delay its advancement and preserve the body's remaining insulin-producing capacity.

Tzield (teplizumab-mzwv) is a monoclonal antibody—a type of protein therapy that targets specific immune cells involved in attacking beta cells. In November 2022, it became the first drug approved by the FDA to delay the progression from stage 2 to stage 3 type 1 diabetes in children ages 8 and older.

Clinical evidence comes from a large integrated analysis of five clinical trials involving 609 patients with stage 3 T1D. Researchers measured C-peptide, a marker of the body's own insulin production. One year after treatment, patients who received Tzield showed an average increase in C-peptide of 0.08 nmol/L compared to controls. By year 2, this improvement grew to an average increase of 0.12 nmol/L. Both improvements were statistically significant.

Tzield also reduced the need for injected insulin. Patients receiving the drug required approximately 0.08 units/kg/day less insulin at year 1, and 0.10 units/kg/day less at year 2, compared to those who did not receive it. These findings demonstrate that Tzield genuinely preserves the pancreas's ability to make its own insulin.

An integrated safety analysis covered nearly 1,500 patient-years of follow-up across five clinical trials involving approximately 1,018 patients. The most commonly reported adverse events were lymphopenia (low white blood cell counts), rash, and headache.

Importantly, the majority of these side effects occurred during and in the weeks immediately following treatment administration. Most resolved without requiring additional intervention. This safety profile is important for families to understand: the drug does affect the immune system, but the effects appear manageable and temporary for most patients.

For decades, type 1 diabetes management focused on controlling blood sugar through insulin therapy, insulin pumps, and continuous glucose monitoring. These tools are essential and life-saving, but they address the symptom, not the underlying disease process.

Tzield represents a new category: disease-modifying therapy. Instead of only replacing insulin after beta cells are damaged, Tzield works upstream—slowing the immune attack itself and preserving beta-cell function before significant loss occurs. Researchers emphasize that this approach has the potential not only to delay disease onset but also to reduce long-term complications associated with type 1 diabetes.

While Tzield is not a cure and does not reverse existing damage, it is a meaningful advancement for families facing a new diagnosis or early autoimmune signs of type 1 diabetes.

Origin: Contemporary Pediatrics (News report). Evidence: News report, corroborated with 2 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.